Rockwell Medical Inc

Rockwell Medical maintains a conservative capital structure with $11.86 million in cash and equivalents, representing 22.4% of total assets, and a current ratio of 2.0. The company's liquidity position is supported by a debt-to-equity ratio of 0.46, with long-term debt accounting for 19.6% of total liabilities. Despite a negative operating cash flow of $938,000, the firm generated $698,000 in free cash flow, indicating some operational flexibility. Profitability metrics show significant underperformance relative to industry norms. The company's return on equity of 1.46% and return on assets of 0.65% fall well below the median for the Pharmaceuticals industry, which typically exceeds 10% ROE and 5% ROA. Gross margin of 17.6% (calculated from $4.55 million gross profit on $25.83 million revenue) is also below the industry median of 60-70% for specialty pharmaceutical firms. Geographic and segment exposure is opaque in the latest disclosures, with no breakdown of revenue by geography or product line provided. This lack of transparency limits assessment of diversification risks. The company operates as a single business unit focused on anemia treatments, with no material revenue from other therapeutic areas. Growth prospects appear constrained, with no revenue history provided for trend analysis. The company's market capitalization of $31.44 million suggests limited scale relative to peers. Analysts have assigned a mean price target of $3.00, implying 277% upside from the current price of $0.7965, but this is based on only two "buy" ratings with no "strong buy" or "hold" designations. Risk factors include the company's high price-to-earnings ratio of 91.66 and price-to-book ratio of 1.34, which suggest potential overvaluation relative to fundamentals. While no immediate dilution or liquidity flags were detected, the absence of positive operating cash flow raises concerns about long-term sustainability without additional financing. The company has not disclosed any recent capital raises or dilutive events in the latest filings. Recent events include the publication of analyst price targets ranging from $2.00 to $4.00, with a median of $3.00. No material earnings reports, regulatory approvals, or product launches were disclosed in the latest available data. The company's 10-K filing history was not included in the source documents, limiting access to more detailed risk disclosures.